Zealand Pharma seeks to challenge GLP-1 dominance with obesity drug aimed at long-term use
Zealand Pharma unveils ambitious five-drug obesity pipeline by 2030, backed by $5.3 billion Roche partnership. Lead candidate petrelintide targets amylin instead of GLP-1, showing superior tolerability in early trials—but stock remains down 28% YTD.
Insights:
Zealand Pharma is mounting an ambitious challenge to the weight-loss drug market dominated by Novo Nordisk and Eli Lilly , unveiling plans to launch five obesity and metabolic drugs by 2030. The Danish biotech company is betting that its differentiated approach—targeting the pancreatic hormone amylin rather than the widely-used GLP-1 pathway—can capture meaningful share of a market analysts project could reach $150 billion annually by decade's end.
At a capital markets day in London 
GB on Thursday, CEO Adam Steensberg positioned existing GLP-1 weight-loss drugs as merely a first step in addressing what he called a civilization-scale health crisis affecting one billion obese people worldwide. The holy grail is not just weight loss, its pleasant long-term weight maintenance, Steensberg told Reuters, citing real-world data showing more than half of patients discontinue GLP-1 therapy within a year and subsequently regain weight.
GB on Thursday, CEO Adam Steensberg positioned existing GLP-1 weight-loss drugs as merely a first step in addressing what he called a civilization-scale health crisis affecting one billion obese people worldwide. The holy grail is not just weight loss, its pleasant long-term weight maintenance, Steensberg told Reuters, citing real-world data showing more than half of patients discontinue GLP-1 therapy within a year and subsequently regain weight.
